


María del Puerto Morales

Instituto de Ciencia de Materiales de Madrid, ICMM/CSIC
Department of Biomaterials and Bioinspired Materials



OUTLINE

1- Nanoparticles for medicine

2- Basic principles in magnetism

3- Biomedical applications: Separation, Diagnosis, Therapy

4- Synthesis of magnetic nanoparticles

5- Future

Nanosystems in medicine

Materials


Nano-porous
Nano-crystals
Nano-reinforced
Nano-structured surfaces

Properties

Tissue ingrowth, transport of substances
Physical, electrical, optical, mechanical properties
Mechanical properties, Biocompatibility

Applications

- Surgery
- Therapy
- Diagnostics
- Biosensors/biodetection
- Implantable materials/devices: Tissue engineering
- Textiles and wound care products
- Drug/gene delivery materials and devices




Bandages with silver nanoparticles
Curad® (www.curadusa.com)
antibacterial agent.

Nanosystems in medicine

Nanotechnology and health care, huge potential and some risks.

Global Market for Nanoparticles



Source: BCC Research (BIO113B), August 2014

Drug delivery

- Drug release control
- Drug solubility problems
- DNA carriers
- Tissue regeneration

Areas: Cancer
Neurodegenerative
Cardiovascular
Infection

Oncology

High mortality without effective treatment

Consequences: The oncology market is the third largest pharmaceutical market, behind the cardiovascular and central nervous system therapy areas.

Treatment of cancer with traditional medicine involves surgery, ionizing radiation, and chemotherapy


These treatments affect both tumors and healthy tissue.

Consequences: Multi-billion markets in medical and palliative expenses because systemic toxicity and undesirable side effects.

Nanoformulaciones aprobadas por diferentes agencias reguladoras

Product	Nanosystem	Application	Status	Company
Doxil (Barenholz, 2012)	Doxorrubicina encapsulada en liposomas PEGilados	Cáncer de ovarios	Aprobado 11/17/1995 FDA50718	Ortho Biotech (adquirida por JNJ)
Myocet (Waterhouse et al., 2001)	Doxorrubicina encapsulada en liposomas No PEGilados	Cáncer de mama metastásico	Europa y Canadá, en combinación con ciclofosfamida	Sopherion Therapeutics, LLC EEUU y Cephalon, Inc. en Europa
DaunoXome (Forssen, 1997)	Daunorrubicina encapsulada en liposomas	Tratamiento de sarcoma de Kaposi avanzado asociado al VIH	Aprobado en E.E.U.U	Galen Ltd.
ThermoDox (Dromi et al., 2007)	Doxorrubicina encapsulada en liposomas (liberación mediada por calor)	Cáncer de mama y primeras etapas de cáncer de hígado	Aprobación esperada para el año 2013	Celsion
Abraxane (Guarneri et al., 2012)	Nanopartículas de albúmina-paclitaxel	Diferentes tipos de cáncer	Aprobado 1/7/2005 FDA21660	Celgene
Rexin-G (Gordon and Hall, 2010)	MicroRNA-122 encapsulado en liposomas	Sarcoma, osteosarcoma, cáncer de páncreas, y otros tumores sólidos	Aprobado en Filipinas, Fase II y III en E.E.U.U	Epeius Biotechnologies Corp.
Oncaspar (Avramis and Tiwari, 2006)	Asparaginasa PEGilada	Leucemia linfoblástica aguda	Aprobado 24/06/2006	Enzon Pharmaceuticals, Inc.
Resovist (Hamm et al., 1994)	Nanopartículas de óxido de hierro recubiertas de carboxidextrano	Agentes de contraste para hígado y bazo	Aprobado en Europa en 2001	Bayer Schering Pharma AG
Feridex (Weissleder et al., 1989)	Nanopartículas de óxido de hierro recubiertas de dextrano	Agentes de contraste para hígado y bazo	Aprobado por la FDA en E.E.U.U en 1996	Berlex Laboratories
Endorem (Weissleder et al., 1989)	Nanopartículas de óxido de hierro recubiertas de dextrano	Agentes de contraste para hígado y bazo	Aprobado en Europa	Guerbet

Magnetic nanoparticles



Iron Oxide


Chem. Soc. Rev., 2012, 41, 4306

Schladt, T. D.; Schneider, K.; Schild, H.; Tremel, W. *Dalton transactions* 2011, 40, 6315

Figuerola, A.; Corato, R. Di; Manna, L.; Pellegrino, T. *Pharmacological Research* 2010, 62, 126


Chemical Design of Biocompatible Iron Oxide Nanoparticles for Medical Applications,
Daishun Ling and Taeghwan Hyeon, *Small* 2013, 9, No. 9–10, 1450–1466,

MAGNETIC NANOPARTICLES ⇔ LIVING SYSTEMS




Fe_3O_4

Polymer



terrestrial

meteorite



Magnetotactic bacteria

For orientation

Life in Mars?

OUTLINE

1- Nanoparticles for medicine

2- Basic principles in magnetism

3- Biomedical applications: Separation, Diagnosis, Therapy

4- Synthesis of magnetic nanoparticles





5- Future

Basic principles


100 nm

Particle size

5 nm




Magnetic recording



Sensors


Basic principles

Superparamagnetic particle




Individual particle

The moments within each particle are ordered (Red arrows)



No magnetic field


The net magnetic moment of a system containing MNPs will be zero in zero field and at high enough temperatures.



Magnetic field


In the presence of a field, there will be a net statistical alignment of magnetic moments

Superparamagnetism



Small particle size

$$\Delta E = K_a V \approx k_B T$$



No particle aggregation

Reversible behaviour


Superparamagnetism

Particle size


Magnetic behaviour

$$\chi \approx \frac{VM_s^2}{3k_B T}$$


Saturation field



Ferromagnetism




Alternating
magnetic field



Delivered by
the applied field

Characterised by area
enclosed by the
hysteresis loop




**Thermal
energy**

Basic principles


MECHANISM OF MAGNETIZATION ROTATION

Néel Loss




Rotation of the moment within the NP

Brown Loss





Mechanical rotation of the NP

Hysteresis Loss



Movement of domain walls in multidomain




MAGNETIC MOMENT RELAXATION TIMES

$$\text{Néel relaxation} = \tau_N = \tau_0 \exp\left(\frac{K V_M}{k_B T}\right)$$


$$\text{Brownian relaxation} = \tau_B = \frac{3 \eta V_H}{k_B T}$$

Total relaxation

$$\frac{1}{\tau} = \frac{1}{\tau_B} + \frac{1}{\tau_N}$$




Basic principles



- Drop of coercive field → less efficient
- No prediction possible

- No hysteresis → no interest for heat
- Analytical calculation : Langevin...

- Open hysteresis loops → **optimized nanoparticles**
- Analytical calculations : Stoner-Wohlfarth model



OUTLINE

1- Nanoparticles for medicine


2- Basic principles in magnetism

3- Biomedical applications: Separation, Diagnosis, Therapy


4- Synthesis of magnetic nanoparticles

5- Future

Biomedical applications




Requirements for biomedical applications



- Nanometer** => **Size:** Get close to a biological entity of interest
=> **Surface:** Bind a biological entity
=> **Properties:** Manipulated by a magnet




Relative sizes of cells and their components




Requirements for biomedical applications

NANOPARTICLES



**COLLOIDAL
SUSPENSIONS**



APPLICATIONS

In vitro


In vivo

REQUIREMENTS

- Size
- Surface
- Properties


No toxic!!

- Stable
- Biocompatible
- Reversible



Size





5-50 nm = Ideal diameter for most forms of therapy



Requirements for biomedical applications


Hydrodynamic size

Core + Molecules around



Surface

Modification of the particle's surface to make it biocompatible and specific




Hydrophilic coating make
to the immune system

with a **biological entity** to
in a specific manner


art and deliver a biological

Requirements for biomedical applications

Surface





Detect virus in body fluids




Recognise and destroy a cancer cell

Magnetic properties



- They must **constantly and rapidly** “flip” magnetic states.
=> $M_r=0$
- **Saturation magnetisation** (M_s) should be **strong enough** to be manipulated by an external magnetic field
- **Resonant respond** to a time-varying magnetic field should be enough to heat up.


Biomedical applications




- Goal: Separate/detect/isolate one type of cell from others, often when the target is present in very small quantities





Reduce the time
Detect lower concentrations



Separation/selection



Dynabeads




Separación y purificación

✓ Detection of proteins at 10^{-18} M = Prostate-specific antigen (PSA)

✓ Detection of DNA at 10^{-21} M **6 orders of magnitude more sensitive**


Magnetic Sorting/Detection



- **High sensitivity**
- **Multiple analytes at one time**
- **Hand-held**
- **Lightweight**
- **Fast**
- **Potential for single-bead detection**


Separation/selection

BIOMOLECULE SEPARATIONS



Green fluorescent Proteins


FOOD QUALITY CONTROL




WATER PURIFICATION (Ar, Pb, Hg, Zn...)

884 millones = Personas que carecen de acceso a fuentes de abastecimiento de agua potable (una de cada ocho)

Biomedical applications





The most powerful technique for diagnosis

Nobel Prize 2003

Paul C. Lauterbur and Sir Peter Mansfield

"for their discoveries concerning magnetic resonance imaging"


Advantage: not use X-Rays nor any other type of "ionizing" radiation

Instead: it is a technique that combines a large magnetic field and some radio frequency antennas


Measure the **relaxation** rate of **protons** in the atoms of **water** within the patient from their excited state to the ground state

NMR Imaging

Protons aligned with a strong magnetic field



high-frequency electro-magnetic pulse



protons out of alignment

"resonance" signal as the proton goes back into alignment





image reflects the water protons in the patient and their chemical association with proteins



NMR imaging

T1



T2




Fig. 22
Coupling of a T_1 - and a T_2 -curve resembles a mountain with a slope. It takes longer to climb a mountain than to slide or jump down, which helps to remember that T_1 is normally longer than T_2 .




MRI made easy

Instituto de Ciencia
de Materiales de Madrid






CSIC

NMR Imaging




Negative contrast from iron oxide



Positive contrast

NMR imaging



Commercial products = 5-10 nm

NMR Imaging

The chemistry of contrast agents in medical magnetic resonance imaging, André E. Merbach and Eva Toth, Wiley, 2001

Shorter relaxation (T_2)
=> **Darker** in the MRI



$$\frac{1}{T_2} = R_2 = \frac{\left(\frac{64\pi}{135000}\right) \gamma^2 N_A M \mu^2}{r D}$$




NP radio

Diffusion coefficient
of water molecules

Concentration
(mole.L⁻¹)

NP magnetic
moment

NMR Imaging



S.-B. Seo et al. / Journal of Colloid and Interface Science 319 (2008) 429–434

Azhar Zahoor Abbasi. *Phys. Chem. C* 2011, 115, 6257


Instituto de Ciencia
de Materiales de Madrid



CSIC

CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS


NMR Imaging




Challenges

Ralph Weissleder

USPIO



NMR IMAGING OF RAT BRAIN DURING 1 HOUR




Arrowheads (Yellow)- Third Ventricle
Arrows (white)- Lateral Ventricle
Arrowheads (blue)- Recess *Inferior Colliculus*

NMR Imaging





Targeted imaging

tumor



NMR Imaging



T1 contrast agents based on ultrasmall iron oxide nanoparticles



NMR Imaging

Fernando Herranz et al

cnic






Multifunctional contrast agents

Imaging technology	Contrast agents	Spatial resolution	Toxicity	Sensitivity	Time Resolution
X-ray CT	Iodinated contrast material	sub-mm	Nephrotoxic	mM	1–2 s
MRI	Gadolinium-based	sub-mm	Nephrogenic systemic fibrosis	mM for Gd-based nM for Fe-based	1–2 s
PET/SPECT	Radioactively labelled agents	mm	Dosimetric exposure	pM	min

Core/Shell Magnetite/Bismuth Oxide Nanocrystals with Tunable Size, Colloidal, and Magnetic Properties

Evaluation as CT agent




Chem. Mater. 2012, 24, 319–324

Nanotechnology 2015

Hybrids


CT+ MRI





Coronal and axial images taken by CT and MRI after the subcutaneous administration of $100\mu\text{L}$ of FeBi@SiPEG (157mM Fe and 14.6mM Bi). The location of the contrast in the left leg of the mouse is marked with a arrow in the CT pictures.

Hybrids


PET + MRI




^{68}Ga -dCNIC-Dextran



dCNIC-Dextran




Biomedical applications



DRUG DELIVERY

Targeting of a drug immobilised on magnetic nanoparticles under the action of an external magnetic field.




IONP ionically or covalently binding a drug

- **Specific** -> Reducing side effects
- **High local concentration** -> Reducing the dosage
- **Problem** -> Field strength

➔ Human preliminary test

Drug carrier systems



IONP ionically
or covalently
binding a drug

Polymer coated
nanosystems
loaded with drugs
and IONPs

Drug loaded
magnetic
micelles

Lipid vesicles
loaded with
drugs and
IONPs

Cytokine **IFN- γ**

Cancer immunotherapy : Activating immune response to removal primary tumor and prevent metastases.


Cytokine: small protein produced by macrophages and T lymphocytes

Activity:



- Activate macrophages production
- Induce cancer cell apoptosis

IFN- γ the most effective cytokine in tumor elimination

Magnetic nanoparticles: Controlled local release of cytokines



Tumor size




- PBS
- DMSA-NP
- IFN-γ
- IFN-γ-DMSA-NP
- IFN-γ-DMSA-NP + campo magnético

Also for induced tumours with 3-methylcholanthrene (MCA)

Drug delivery

Main limitation



- Large MNPs (> 200 nm) will be easily detected by the immune system and removed from the blood and delivered to the liver and the spleen.
- Very small MNPs (< 5.5 nm) can be excreted through the kidneys.
- Different magnetic biocomposites can be transported to reach the tumor area inside the body thanks to the applied magnetic field.

Challenges

Nanoparticle-based chemotherapy

Proof-of-principle, in vivo studies

Nanoparticle-based radiotherapy

In vitro and in vivo studies

Nanoparticle-based phototherapy

Proof-of-principle


Drug delivery across blood-brain barrier

- Treatment of brain tumours, Alzheimer's, and Parkinson's – *development phase*
NanoDel Technologies GmbH, Germany

Nanovectors for gene therapy

- Non-viral gene delivery systems – *in vitro studies*


Delivery of genetic materials (siRNA and pDNA) into stem cells




Delivery of siRNA against SOX9 (siSOX9) and CAVEOLIN-1 (siCAV) gens for inducing neural differentiation of NSCs

Angew. Chem. Int. Ed. 2013, 52, 6190–6195


Experiment (proliferation)





Experiment (differentiation)



Experiment (with MF)




Control (without MF)



TUJ1= Neurons, MBP= Oligodendroncytes


Biomedical applications



Hyperthermia

HYPERTHERMIA



Heating of a target tissue to the temperatures between 42-43 °C




42-43°C

- Reduces the viability of cancer cells
- Increases their sensitivity to chemotherapy and radiation

Conventional Hyperthermia



Magnetic Hyperthermia



Advantages of using magnetic nanoparticles



- Avoid heating healthy tissues
- Combining other therapies
Targeting radionuclides

42°C / 30 min → Cancer is destroyed

Goya et al, Current Nanoscience 2008, 4, 1-16

Nearly complete regression of tumors via collective behavior of magnetic nanoparticles in hyperthermia, C L Dennis et al., Nanotechnology 20 (2009)

What we actually measure...



$$\text{SAR} = C_m \phi(\Delta T / \Delta t)$$

Important parameters

Specific Absorption Rate = Specific Loss Power = **Experimental**

$$\text{SAR} = C_m \phi(\Delta T / \Delta t)$$




$$\text{SLP} = \mu_0 \cdot \pi \cdot f \cdot H^2 \cdot \chi''(f)$$

where C_m is the specific heat capacity of the sample

Specific hysteresis loss = **SHL** = **Theoretical area**

Intrinsic Loss Parameter = **ILP** = **SAR / $H^2 \cdot f$**



Hyperthermia



G. Salas, et al., International Journal of Hyperthermia, 29, 8, 768-776, 2013


EFFECT OF NP CONCENTRATION

IMDEA Nanoscience (Madrid)



Dependence of the SAR values for magnetite colloids, at different H_{MAX} for a given frequency (107 kHz). Arrows depict the concentration at which the SAR value is maximum for each H_{MAX}


A Single Picture Explains Diversity of Hyperthermia Response of Magnetic Nanoparticles



Non-monotonic concentration dependence of heating efficiency



- Intrinsic features
- Experimental conditions

J. Phys. Chem. C, **2014**, *118* (11), pp 5927
Langmuir, **2016**, *32* (5), pp 1201–1213




NANOPARTICLE ASSEMBLING

David Serantes, I. Conde-Leborán, D. Baldomir, K. Simeonidis, M. Angelakeris, Ò. Iglesias, O. Chubykalo-Fesenkoa and C. Martínez-Boubeta



- The highest area $M(H)$ curve is attained for chain-like shape




- Dependence of area $M(H)$ curve on chain length and orientation

Chain-like arrangements produce higher hyperthermia output (up to 5 times!)

HeLa and MDA-MB-231 cells (stained with Hoechst 33258) were incubated with DMSA coated NPs, and exposed to an AC magnetic field (AMF).


24 h after the treatment apoptotic cells (HeLa) and giant and multinucleated cells (MDA-MB-231) were observed.



DMSA (anionic)

AMF conditions: 161 kHz, 210 G, 15 min exposure (HeLa cells),
225 kHz, 150 G, 45 minutes exposure (MDA-MB-231 cells).

Thermal damage Non-thermal damage




Intracellular hyperthermia at different specific absorption rates.


VOL. 5 ' NO. 9 ' 7124-7129 ' 2011 acsnano

No perceptible change in temperature

Lysosomal Membrane Permeabilization by Targeted Magnetic Nanoparticles in Alternating Magnetic Fields



ACS Nano 2013, 10.1021/nn405356r



Hyperthermia could be used to locally modify tumor stroma and thus improve drug penetration

Hyperthermia

Table 3. Summary of nanoparticle features favoring MRI and/or magnetic hyperthermia applications.

MRI (contrast)	Nanoparticle feature	Magnetic hyperthermia (heating)
+	High magnetization (size and surface coating)	+
+	SPIO	-
+	USPIO	-
+/-	Large size (core diameter >10 nm)	+
+	Sequestration by MPS	-
-	Long plasma half-life (targeting)	+
+	Short plasma half-life (targeting)	-

+: Favoring feature/parameter; -: Disfavoring feature/parameter; MPS: Monocyte phagocyte system; SPIO: Superparamagnetic iron oxide; USPIO: Ultrasmall superparamagnetic iron oxide.


Ingrid Hilger et al., Nanomedicine 2012

<http://www.magforce.de/en>

http://www.youtube.com/watch?v=BZLmD3SOR_Y

<http://www.clinicaltrials.gov/ct2/show/study/NCT00003052>

<http://www.mhaus.org/>



NanoTherm™ therapy

NanoTherm™

NanoPlan®

NanoActivator®

Fighting cancer more effectively and with fewer side effects

HOW DOES NANOTHERM™ THERAPY WORK?

NanoTherm™ therapy is a new approach to the local treatment of solid tumors. The method is based on the principle of introducing magnetic nanoparticles directly into a tumor and then heating them in an alternating magnetic field. At approximately 15 nanometers in diameter, the nanoparticles, which are suspended in water, are extremely small (a nanometer is one millionth of a millimeter), and comprise an iron oxide core with an aminosilane coating. The particles are activated by a magnetic field that changes its polarity up to 100,000 times per second, generating heat.



 Compliant with European Standard



NanoTherm™



Overview

New glioblastoma study

Patient Information

Physicians' Information

Publications

Contact

Growing nanomedicine into a cancer therapy of the future


CLINICAL TRIALS/ TUMOR TYPES	STATUS OF TRIALS		EU Regulatory Approval
	Phase I Feasibility study	Phase II Efficacy study	
Glioblastoma multiforme			
Prostate carcinoma			
Pancreatic carcinoma			




[Study results](#)

LIMITATIONS

Blood interaction




Biological barriers




Y. Okuhata, *Adv. Drug Del. Rev.*, 1999.

TOXICITY

Nanoparticle-cell interactions




Design a nanoparticle for each application




HeLa cells-DMSA

0,5 mg Fe/mL- 24 horas




MTT TEST




Interaction with cells

HeLa cells

Fluorescence and optical microscopy show that cytoskeleton is not affected by the presence of the NPs.
Scale bar: 10 μm .



Problem: Biodistribution




100 mg Fe => Endorem
(1-5 mg/Kg)

Distribution of Iron in Adults

NANCY C. ANDREWS



The New England Journal of Medicine
Volume 341 Number 26, 1986, 1999

Magnetisation curves





All materials are magnetic to some extent with their magnetic response depending on their atomic structure and temperature

Susceptibilidad AC



Biodistribution in vivo: Magnetic methods




Liver and brain imaging through dimercaptosuccinic acid-coated iron oxide nanoparticles
 Nanomedicine 5(3), 397- 408, 2010

Biodistribution: Characterization



AC MAGNETIC SUSCEPTIBILITY






With the appropriated standards it is possible to calculate the amount of the total iron that is in the form of the magnetic nanoparticles.

Biodistribution




In vivo


Coating



a)



b)



Biodistribution



In vivo


Anesthesia




Ketamine and xylazine
Intraperitoneal




Isoflurane
Inhaled (0.5% in oxygen)



A) Ketamine/xilacine



B) Isoflurane




Biodistribution




In vivo

External magnetic field




Legend for Tumor Volume (mm³):

- PBS (Dark Blue line)
- DMSA-MNP (Medium Blue line)
- IFN- γ (Purple line)
- IFN- γ -DMSA-MNP (Pink line)
- IFN- γ -DMSA-MNP + Magnetic field (Light Pink line)




Quantification of NPs in tumor


Susceptibilidad magnética









NP-γ-IFN



NP-γ-IFN- Magnet




Long term particle transformations




Future Research

Contrast agents



- More efficient agents
- Targeting
- Multimodal imaging agents
 - MRI/TC
 - MRI/PET

Transporte de fármacos



- NP-Chemotherapy
- NP-Radiotherapy
- NP-Phototherapy
- Across the blood-Brain barrier
- Gene therapy

Hipertermia


magforce[®]
THE NANOMEDICINE COMPANY



- Optimization of agents and heat generator
- Mechanism of cell death
- i.v. injection


New applications

Pulse Therapeutics




<http://scitation.aip.org/content/aip/magazine/physicstoday/news/10.1063/PT.5.5029>

Regeneration




Angewandte Chemie International Edition
53, 6369-6373, 16 APR 2014 DOI: 10.1002/anie.201401043



single red blood cell is the same width as about 2000 nanoparticles.

Detecting disease early



Nanoparticles circulate in the blood and can be built to attach to particular types of cells, such as circulating cancer cells.

A device worn on the outside of the body can detect the nanoparticles and provide useful information to physicians.

OUTLINE

1- Nanoparticles for medicine

2- Basic principles in magnetism


3- Biomedical applications: Separation, Diagnosis, Therapy

4- Synthesis of magnetic nanoparticles



5- Future

Design a Nanoparticle for each application

IMPORTANT PARAMETERS




- Different core size
- Different core composition




- Biocompatible polymers
- Colloidal stability
- Strong anchoring
- > MNPs blood life-time
- Core protection

UNIFORM NANOPARTICLES



Upon application, only a small number of particles contribute to the desired magnetic effect.

Nanoparticle synthesis routes



Modelo Clásico
LaMer and Dinegar

Synthesis and Characterization of Nanoparticles: Synthesis of Inorganic Nanoparticles,
Gorka Salas, Rocio Costo and María del Puerto Morales
Part I, Vol. 4 Nanobiotechnology, Inorganic Nanoparticles vs Organic Nanoparticles
edited by J.M. de la Fuente and V. Grazu, 2012 Elsevier Ltd, FRONTIERS OF
NANOSCIENCE, Series, Editor: R. E. Palmer, UK.


Instituto de Ciencia
de Materiales de Madrid




CSIC

CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS

Nanoparticle synthesis routes



Nanoparticle synthesis routes



Nanoparticle synthesis routes

TABLE 2.1 Summary Comparison of the Synthetic Methods.

Synthesis Method	Reaction Time	Solvent	Surface-Capping Agent	Sizes	Size Distribution	Shape Control	Yield
Coprecipitation	Minutes	Water	No	2–15	Broad	Not good	Medium
Thermal decomposition	Hours–days	Organic compound	Yes	4–30	Very narrow	Very good	Medium
Polyol process	Hours	Polyglycol	Yes	5–150	Narrow–broad	Good	Medium
Microemulsion	Hours	Organic compound	Yes	5–50	Narrow	Good	Low
Spray pyrolysis	Seconds	Water and volatile solvents	No	2–10	Broad	Not good	High
Laser pyrolysis	Milliseconds	Gases	No	2–10	Very narrow	Good	High


Synthesis and Characterization of Nanoparticles: Synthesis of Inorganic Nanoparticles,

Gorka Salas, Rocio Costo and María del Puerto Morales
Part I, Vol. 4 Nanobiotechnology, Inorganic Nanoparticles
vs Organic Nanoparticles edited by J.M. de la Fuente and
V. Grazu, 2012 Elsevier Ltd, FRONTIERS OF
NANOSCIENCE, Series, Editor: R. E. Palmer, UK.

Coprecipitation

Sal de Fe(II) y Fe(III)


$$\text{Fe}^{2+}/\text{Fe}^{3+} = 0.5$$



- Concentration
- Temperature
- Atmosphere
- Stirring





Fe_3O_4
(Magnetite)

Synthesis by precipitation in water




Instituto de Magnetismo Aplicado
Laboratorio "Salvador Velayos"
UCM-ADIF-CSIC




$H = 100 \text{ Oe}$
 $f = 522.7 \text{ Hz}$
 $c = 50 \text{ mg/ml}$



Synthesis by precipitation in water



APS coating




D core= 6.3 nm (PDI=0.2)
D hyd= 47.81 nm (PDI=0.23)

D core= 13.7 nm (PDI=0.2)
D hyd=106.3 nm (PDI= 0.17)

Synthesis by precipitation in water

Sal de Fe(II)



90°C ± 0.1
24 hours

Undisturbed system

Aqueous solution
Na(OH) + KNO₃

Synthesis by precipitation in water





Control de la oxidación

150 nm

95 nm

70 nm

30 nm



200 nm






[Fe(II)] concentration decreases

[OH]_{exc} increases from 0.0002 M to 0.02 M


Particle size decreases from 300 nm to 30 nm

Hyperthermia + Dual imaging agent (NMR + CT)

Core/Shell Magnetite/Bismuth Oxide Nanocrystals with Tunable Size, Colloidal, and Magnetic Properties



High temperature decomposition of organic precursors




Atmosphere control

Temperature control (200-400°C)







Surfactante

- El surfactante tiene la habilidad de controlar el crecimiento de la partícula
- Combinando diferentes surfactantes es posible controlar tamaño y forma de partícula.








High temperature decomposition of organic precursors





Precursor



High temperature decomposition of




High temperature decomposition of organic precursors



High temperature decomposition of organic precursors

Size control



Iron oxide nanoparticles showing one nanometer increments in diameter

Roca, A. G. et al *Nanotechnology* **2006**, *17*, 2783-2788.

IEEE TRANSACTIONS ON MAGNETICS, 42, 3025 (2006)


Instituto de Ciencia
de Materiales de Madrid




CSIC

CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS

Problems: low Ms at larger sizes




Park, J. *et al. Nat. Mater.* **2004**, 3, 891-895




Broad size-distribution

Other phases




wüstite-spinel core-shell structure



Pichon *et al Chem. Mater.* **2011**, 23, 2886-2900

Structural imperfections



| *Chem. Mater.* 2011, 23, 4170–4180


Hydrophilic Nanoparticles

The major challenge in the development of nanoparticles for biomedical applications is to make them hydrophilic, stable at physiological conditions and without significant aggregation.


Easy and reproducible experimental set up.

Functional groups for water stability.


Ready for further functionalization.




Hydrophilic Nanoparticles



Encapsulation in polymers




Morales et al., J. Mater. Chem., 2009, 19, 6381; J. Phys. Chem C 2011




Pita et al, Journal of Colloid and Interface Science 321 (2008) 484–492

Ligand exchange or modification




F. Herranz et al., Chemistry - A European Journal, 14, p 9126 2008 Contrast Media Mol. Imaging 2008, 3 215–222

Laser Pyrolysis




S. Veintemillas-Verdaguer, O. Bomati-Miguel and M.P. Morales. **Scripta Mater.**, 47, 589-593 (2002)

MECHANISM OF NANOPARTICLE FORMATION



The C_2H_4 absorbs the laser energy, $Fe(CO)_5$ is rapidly heated and decomposed resulting atomic Fe saturated vapour and leads to the nucleation and growth of iron metal nucleus



To stabilise the powders, a mixture of air and ethylene can be introduced together with the iron pentacarbonyl (hard oxidation) or after the laser pyrolysis (soft oxidation).

Laser Pyrolysis











Figure 4.35: Field Cooling hysteresis loops of the samples at 5, 15, 30 and 50K. The insets show the low field area where the loop shift and the coercivity increase can be clearly observed.



Microwave



Polyol Mediated Process



✓ $\uparrow \epsilon_r, \uparrow T_B$

✓ Hydrophilic coating

✓ Easily dispersed in aqueous media and other polar solvents



✓ $\uparrow T$ favors higher crystallinity and $\uparrow M_s$

✓ Narrow Size distribution





Other reagents present:
Iron precursor, precipitator, surfactant/stabilizer

Polyol Mediated Process

VARYING THE CORE SIZE OF THE NANOFLOWER



heating
time (h)



- \uparrow heating time, $\uparrow d_{\text{XRD}}$
- Core grows exponentially over time
- Particle size remains unchanged

Shape control

Induced anisotropy growth

Anisotropic growth along a particular direction => choosing appropriate capping reagents (e.g. surfactant and additives)



The density of Fe atoms on the surface of $\{100\}$ and $\{110\}$ is higher than that on the $\{001\}$ facet. Phosphate and amine bond preferentially onto $\{100\}$ and $\{110\}$ facets through covalent bonding rather than on the $\{001\}$ facet.

Phosphate and amine


Elongated nanoparticles

Silicate anions and citric acid (CA)

Discs or prismatic



- There is an urgent for development of adequate **testing protocols and metrology standards** to assess the quality and hazard of, and exposure to nanomaterials.
- **NanoMag project** addresses this task in the field of magnetic nanoparticles for medical applications.
- We have to **defined and standardized ways of analysing these nanostructures**.
 - ✓ Define the **relevant measurands**
 - ✓ Describe the available techniques : their **limits, uncertainty**
 - ✓ Summarize existing standards and develop **new standards**
 - ✓ Provide **reference materials**



Wrapping up

- Thermal decomposition require :
 - Long reaction times and high temperatures
 - Control of the oxygen free atmosphere
 - Toxic reagents and byproducts
 - Particles are hydrophobic= need extra steps
- Hydrothermal/Solvothermal methods produce high quality nanoparticles with relatively lower reaction temperatures (<200°C), relatively simple equipment and process. Polyol process allow using higher temperatures (~250°C) and render hydrophilic nanoparticles.


Toward the standardization of the synthesis of magnetic nanoparticles

- Homogeneous temperature distribution for large scale production
- Short reaction times


Summarizing

Magnetic nanoparticles could help to improve clinical practice in the treatment of cancer, most probably in synergy with other conventional treatments.


Imaging agents



Therapeutic agents



Magnetic nanoparticles advantages



Magnet assisted

AKNOWLEDGEMENTS



Thank you!!!!

BIOMEDICAL

Cell therapy

Dr. Angeles Villanueva (UAM)

Dr. Domingo Barber (CNB)

MODELLING

Dr. Oksana Chubykalo-Fesenco (ICMM)

CHARACTERISATION

Magnetic properties

Jana Vejpravova (A. of Science)

Daniel Niznansky (Charles U.)

Patricia de la Presa (IMA)

Heating efficiency

Dr. Gorka Salas (IMDEA Nanoscience)

Dr. Francisco Terán (IMDEA Nanoscience)

Prof. Marc Respaud (INSA, Toulouse)

Prof. Ingrid Hilger (UJH, Jena)

NMR imaging

Dr. Fernando Herranz (CNIC)

Prof. Jesús Ruiz Cabello (CNIC)



seit 1558



AXA
Research Fund
Through Research, Protection

REFERENCES

- Biological Applications of Magnetic Nanoparticles, Miriam Colombo, Susana Carregal-Romero, Maria F. Casula, Lucía Gutiérrez, María P. Morales, Ingrid B. Böhm, Johannes T. Heverhagen, Davide Prosperi, Wolfgang. J. Parak, Chemical Society Reviews , 41, 4306-4334, 2012
- Scientific and industrial challenges of developing nanoparticle-based theranostics and multimodality contrast agents for clinical application, Yi Xiáng J. Wáng, Jean-Marc Idée and Claire Corot, Nanoscale, 2015, 7, 16146.
- Chemical Synthesis and Assembly of Uniformly Sized Iron Oxide Nanoparticles for Medical Applications, Daishun Ling, Nohyun Lee, and Taeghwan Hyeon, Acc. Chem. Res. 2015, 48, 1276–1285.
- Magnetite nanoparticles for cancer diagnosis, treatment, and treatment monitoring: recent advances, Materials Today Volume 19, Number 3 April 2016
- Free course on magnetic nanoparticles for biomedical applications, <http://www.npl.co.uk/commercial-services/products-and-services/training/e-learning/magnetic-nanoparticles-standardisation-and-biomedical-applications/>